Active Vimentin (VIM) Homo sapiens (Human) Active protein

Add to Cart Distributors
Overview
Properties
  • Buffer Formulation20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder, Purity > 97%
  • Isoelectric Point5.2
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Vimentin (VIM) Packages (Simulation)
  • Active Vimentin (VIM) Packages (Simulation)
  • Active Vimentin (VIM) Figure . Gene Sequencing (extract)
  • APB040Hu01.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Vimentin (VIM) is a type III intermediate filament (IF) protein that is expressed in mesenchymal cells.vimentin is the major cytoskeletal component of mesenchymal cells. Because of this, vimentin is often used as a marker of mesenchymally-derived cells or cells undergoing an epithelial-to-mesenchymal transition (EMT) during both normal development and metastatic progression. Besides, Keratin 20 (KRT20) has been identified as an interactor of VIM, thus a binding ELISA assay was conducted to detect the interaction of recombinant human VIM and recombinant human KRT20. Briefly, VIM were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μl then transferred to KRT20-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-VIM pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µl stop solution to the wells and read at 450nm immediately. The binding activity of VIM and KRT20 was shown in Figure 1, and this effect was in a dose dependent manner.

Usage

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Aberrant Vimentin Methylation Is Characteristic of Breast Cancerpubmed:22315367
  • Glyoxalase 1-knockdown in human aortic endothelial cells - effect on the proteome andendothelial function estimates.pubmed:27898103
  • HtrA3 is a cellular partner of cytoskeleton proteins and TCP1α chaperoninPubmed:29477555
  • Growth hormone induces Notch1 signaling in podocytes and contributes to proteinuria in diabetic nephropathyPubmed: 31511328
  • Extracellular vesicles derived from injured vascular tissue promote the formation of tertiary lymphoid structures in vascular allograftsPubmed: 31729155
  • Is Vimentin the Cause or Effect of Obstructive Sleep Apnea Development?Pubmed: 32088750
  • ZNF471 modulates EMT and functions as methylation regulated tumor suppressor with diagnostic and prognostic significance in cervical cancer33566221
  • Metastatic suppression by DOC2B is mediated by inhibition of epithelial-mesenchymal transition and induction of senescence33758996
  • Comparison of Vimentin Levels Between Preeclamptic and Normotensive Pregnant Women
  • Advanced glycation end-products associate with podocytopathy in type II diabetic patients
  • Non-POU Domain-Containing Octamer-Binding (NONO) Protein Stability Regulated by PIN1 is Crucial for Breast Cancer Tumorigenicity Via the MAPK/β …

Recommend products